Newsroom

Greater awareness and advances in treatment have greatly improved survival rates following heart attack. With more survivors, however, has come the challenge of managing long-term impacts on heart function, especially chronic heart failure, in which the heart gradually loses its ability to pump blood.

An ongoing challenge of cancer treatment is finding a way to use powerful chemotherapies to attack tumor cells while minimizing toxic side effects. A recent study by researchers at the Lewis Katz School of Medicine at Temple University and Fox Chase Cancer Center has demonstrated a potential new way to avoid this problem by using nanoengineered stem cells as a drug delivery system.

Temple Health is one of 42 health systems nationwide selected to participate in the Patient-Centered Outcomes Research Institute (PCORI)’s Health Systems Implementation Initiative (HSII) to accelerate the uptake of practice-changing research results in clinical care to improve quality and patient outcomes. The goal of this multi-year PCORI initiative is to help cut the estimated 17-year lag between publication of medical research results and their widespread implementation in real-world practice settings.